PPBT

1.5250.33%
EK

Eric K. Rowinsky

Independent Chairman of the Board

Dr. Eric K. Rowinsky, M.D, is Clinical and Medical Lead of Seed Therapeutics, Inc. Dr. Eric is Acting Chief Medical Officer of Nectin Therapeutics Ltd. He was Head Medical Advisor of Aleta Biotherapeutics, Inc. from October 2025 to February 2026 and also serves as Clinical Advisor since February 2026. Dr. Rowinsky is Member of Industry Advisory Board of Radyus Research, Inc. Dr. Rowinsky is Director at Inspirna Inc. Dr. Rowinsky is Consulting Chief Medical Officer of Flashpoint Therapeutics, Inc. from 2025. He serves as member of Investment Advisory Board at DROIA nv. He serves as Member of Scientific Advisory Board of AI Proteins, Inc. since May 2023. He serves as Chief Medical Officer at OncoTartis, Inc., Innovative Cellular TherapeuticsNeophore, SEED Therapeutics, C-Bridge Capital and NANOMETICS LLC. He served as Chief Medical Officer at Hummingbird Bioscience Pte. Ltd. since July 2021 to March 2023. He has been an Independent Chairman of the Board at Purple Biotech Ltd. (formerly known as Kitov Pharma Ltd) since October 2019. He has also been a consulting Chief Medical Officer for Hummingbird Biosciences since February 2020 and served as the Chief Scientific Officer of Clearpath Development Co. from June 2016 to August 2021. Dr. Rowinsky served as Chief Medical Officer of Hummingbird Bioscience Pte. Ltd from 2020 to 2023. He served as Member of Scientific Advisory Board at Everest Medicines Limited until 2023. Dr. Rowinsky served as the Chief Scientific Officer of Oncology at Clear Path Development Company, a biotechnology company that Partners with leading biopharmaceutical companies to expand early product pipeline opportunities and minimize financial impact since June 2016. Dr. Rowinsky served as the President of Inspirna, Inc. (formerly known as Rgenix, Inc.)., since November 2015 and served as its Chairman of Clinical Advisory Board and served as its Executive Chairman from December 2016 to September 2021. He also served as the Chief Scientific Officer of Clearpath Development Inc from 2016 to 2021 and has served as a consulting Chief Medical Officer of Oncotartis, Inc. since 2018 and Everest Medicines, Inc. since 2017. He served as Director at Biophytis SA from 2018 to October 29, 2019. Dr. Rowinsky serves as Chief Medical Officer of Mitra Biotech Pvt Ltd. He served as Consultant of Stemline Therapeutics, Inc. since October 27, 2015. Dr. Rowinsky served as a Consultant of Fortress Biotech, Inc. since October 2010. He serves as Consultant/Scientific Advisor to multiple biotech and pharmaceutical companies in cancer drug development. He has been an Independent Consultant since January 2010. He has been Strategic Advisor for Oncology Product Development at RRD International, LLC since March 2010 and oversees oncology product development. From 2005 to 2010, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. Dr. Rowinsky served as the Chief Medical Officer, Head of Research & Development and Executive Vice President at Stemline Therapeutics, Inc. from 2012 to October 2015. He served as the Chief Medical Officer and Scientific Advisor of Champions Biotechnology, Inc. (now Champions Oncology, Inc.). Dr. Rowinsky was Co- Founder of Primrose Therapeutics (acquired by Kadmon Therapeutics Inc.) and served as its Chief Executive Officer from June 2010 to September 2011. Dr. Rowinsky served as a Scientific Advisor to ImClone Systems Corporation. He has many of research and drug development experience, oncology expertise and broad scientific and medical knowledge. He served as Chief Medical Officer of ImClone Systems Corporation from February 21, 2005 to 2007 and served as its Executive Vice President of Clinical Development and Regulatory Affairs from December 2007 to 2009. He was Senior Vice President of Clinical Research at ImClone Systems LLC from February 21, 2005 to December 2007 and its Chief Medical Officer since February 21, 2005 and Executive Vice President since December 2007. Dr. Rowinsky served as Senior Vice President of Clinical Research at ImClone Systems Corporation from February 21, 2005 to December 2007. He joined ImClone in 2005. He also served as a drug development and regulatory strategy consultant to the ImClone-Lilly Oncology Business Unit and several other biopharmaceutical and life sciences companies from 2010 to 2011. He served as Chief Medical Officer of Lilly/CTRC and JHMI. He served as Scientific Advisor at Champions Oncology, Inc. From 1996 to 2010, he served as a Director of the Institute of Drug Development of the Cancer Therapy and Research Center in San Antonio, Texas. From 1996 to 2004 he held several positions at the Cancer Therapy & Research Center Institute for Drug Development, including Director of the Institute and Director of Clinical Research. He served as Director of Clinical Research and SBC Endowed Chairman for Early Drug Development at the IDD of the Cancer Therapy and Research Centre in San Antonio, Texas. He served on active staff at the Johns Hopkins School of Medicine from 1988 to 1996. He had been Executive Chairman of Inspirna, Inc. (formerly known as Rgenix, Inc.). since December 2016 to 2021 and its Executive Director since November 9, 2015. He has been Chairman of Clinical Advisory Board at Inspirna, Inc. (formerly known as Rgenix, Inc.). since November 9, 2015. He serves as the Chairman of Clinical Advisory Board at OncoVista Innovative Therapies, Inc. He served as Chairman of the Scientific Advisory Board at BioTheryX, Inc. He served as Chairman of Navidea Biopharmaceuticals, Inc. from September 22, 2016 to March 28, 2018. He served as the Chairman of Clinical Advisory Board at Aviation Upgrade Technologies Inc. He served as the Chairman of the Scientific Advisory Board at Navidea Biopharmaceuticals, Inc. until March 28, 2018. He served as Vice Chairman of the Board at Fortress Biotech, Inc. from October 2010 to May 23, 2024 and served as its Director from October 2010 to May 23, 2024. He had been Member of Scientific Advisory Board at I-Mab since June 2019. Dr. Rowinsky had been a Director of Navidea Biopharmaceuticals, Inc (2010-2018), BIND Therapeutics, Inc. since September 2014 until 2016. He has been Independent Director of Verastem, Inc. since May 3, 2017. He has been Director of BioXcel Corporation since January 5, 2017. He has been an Independent Director of Biogen Inc. since March 2010. He serves as a Director of Immunexcite, Inc. and DLVR Therapeutics Inc. He serves on numerous scientific and oncology advisory boards for biotechnology and pharmaceutical companies. He serves as Member of Clinical Advisory Board at Supratek Pharma Inc. He serves as Member of Scientific Advisory Board at OncoVista Innovative Therapies, Inc. Dr. Rowinsky served as a Member of Oncology Clinical Advisory Board at Mirati Therapeutics, Inc. He served as a Director of Navidea Biopharmaceuticals, Inc from July 16, 2010 to March 28, 2018. He served as a Memb

Positions